Powered by

Corbus Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update

NORWOOD, MA --(Marketwired - March 09, 2017) -

-- Q4 2016 marked by positive data from Phase 2 study of JBT-101 for the treatment of systemic sclerosis showing clear signal of clinical benefit -- Topline data for Phase 2 cystic fibrosis study expected to be reported by the end of Q1 2017 -- Company has sufficient capital to fund its operations into the fourth quarter 2018

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox